MedPath

Prospective, Randomized Open Trial to Evaluate the Efficacy of Highly Purified Urinary FSH (Fostipur®, IBSA) versus Recombinant FSH (Bemfola® Finox) in Oocyte Donors Undergoing Controlled Ovarian Stimulation Based on Receptor N680S FSH Gene Polymorphism

Conditions
Ovarian stimulation for oocyte donation.
MedDRA version: 18.1Level: LLTClassification code 10021940Term: Infertility, female, of unspecified originSystem Organ Class: 100000004872
Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13]
Registration Number
EUCTR2015-003779-31-ES
Lead Sponsor
INSTITUTO BERNABE
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Authorised-recruitment may be ongoing or finished
Sex
Female
Target Recruitment
Not specified
Inclusion Criteria

Be considered apt to get into the oocyte donation program of Instituto Bernabeu
Age between 18 and 30 years
Body Mass Index over 18 and under 28
Antral follicle count greater than 9 and less than 25 (adding both ovaries)
Patients starting ovarian stimulation with 225 IU of FSH
Presence of both ovaries
Ability to participate and comply with the study protocol
Signing the written consent form
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 180
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Not suitable for inclusion in the oocyte donation program of Institute Bernabeu.
Concurrent participation in another study

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath